Cargando…

A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?

Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but it...

Descripción completa

Detalles Bibliográficos
Autores principales: Betzel, Bark, Drenth, Joost PH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148002/
https://www.ncbi.nlm.nih.gov/pubmed/25164119
http://dx.doi.org/10.1186/s12916-014-0152-z
_version_ 1782332545971519488
author Betzel, Bark
Drenth, Joost PH
author_facet Betzel, Bark
Drenth, Joost PH
author_sort Betzel, Bark
collection PubMed
description Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invasive techniques that accurately quantify liver steatosis are warranted. Jiménez-Agüero and colleagues propose that multi-echo magnetic resonance imaging might be such a diagnostic tool. They validated multi-echo magnetic resonance imaging with measured hepatic triglyceride concentration. Their results show that this innovative technique measures the grade of steatosis in different clinical situations. Therefore, multi-echo magnetic resonance imaging might be considered for monitoring liver steatosis as an intermediate endpoint. Wide clinical applicability is limited though, as it does not allow differentiation between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
format Online
Article
Text
id pubmed-4148002
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41480022014-08-29 A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease? Betzel, Bark Drenth, Joost PH BMC Med Commentary Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invasive techniques that accurately quantify liver steatosis are warranted. Jiménez-Agüero and colleagues propose that multi-echo magnetic resonance imaging might be such a diagnostic tool. They validated multi-echo magnetic resonance imaging with measured hepatic triglyceride concentration. Their results show that this innovative technique measures the grade of steatosis in different clinical situations. Therefore, multi-echo magnetic resonance imaging might be considered for monitoring liver steatosis as an intermediate endpoint. Wide clinical applicability is limited though, as it does not allow differentiation between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. BioMed Central 2014-08-26 /pmc/articles/PMC4148002/ /pubmed/25164119 http://dx.doi.org/10.1186/s12916-014-0152-z Text en © Betzel and Drenth; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Betzel, Bark
Drenth, Joost PH
A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
title A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
title_full A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
title_fullStr A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
title_full_unstemmed A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
title_short A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
title_sort new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148002/
https://www.ncbi.nlm.nih.gov/pubmed/25164119
http://dx.doi.org/10.1186/s12916-014-0152-z
work_keys_str_mv AT betzelbark anewnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease
AT drenthjoostph anewnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease
AT betzelbark newnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease
AT drenthjoostph newnoninvasivetechniqueforestimatinghepatictriglyceridewillliverbiopsybecomeredundantindiagnosingnonalcoholicfattyliverdisease